LEXX earnings: next report 2026-10-28, real EPS beat/miss history, analyst consensus Buy, P/E -1.58. Updated 2026-07-23.
Lexaria Bioscience (LEXX) Research Hub
Lexaria Bioscience (LEXX) trades on NASDAQ, CA in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.97 USD (-39.85%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.58, market cap 0.01B. This hub links to the full technical, earnings and options research available for LEXX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CA |
| Last close | 3.97 USD (-39.85%) |
| 52-week range | 3.645 USD – 14.37 USD |
| Trend regime | Range |
| 14-day RSI | 47.2 (Neutral) |
| Trailing P/E | -1.58 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-10-28 |
Available research for LEXX
Covered Call on LEXX: how it works, illustrative setup around the real 3.97 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LEXX: how it works, illustrative setup around the real 3.97 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LEXX: how it works, illustrative setup around the real 3.97 USD price, max profit/loss, breakeven and when to use it. Educational.
LEXX technical analysis: range, last 3.97 USD, RSI 47.2, 52w range 3.645 USD–14.37 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is LEXX in?
Lexaria Bioscience (LEXX) is classified under Healthcare (Biotechnology), listed on NASDAQ, CA.
Is LEXX in an uptrend or downtrend?
As of 2026-09-11, LEXX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LEXX's trailing P/E ratio?
LEXX's trailing P/E is -1.58, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does LEXX next report earnings?
LEXX is next scheduled to report earnings on 2026-10-28, with a consensus EPS estimate of -0.06 USD.